- Home
- CUE vs ABOS Comparison
CUE vs ABOS Comparison
Compare CUE & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | ABOS |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.5M | 197.9M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CUE | ABOS |
|---|---|---|
| Price | $28.95 | $2.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $120.00 | $8.00 |
| AVG Volume (30 Days) | 202.0K | ★ 340.2K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $1.21 |
| 52 Week High | $45.50 | $3.60 |
Technical Indicators
Market Signals| Indicator | CUE | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 61.79 |
| Support Level | $24.70 | $2.13 |
| Resistance Level | $33.95 | $3.02 |
| Average True Range (ATR) | 3.76 | 0.18 |
| MACD | 0.19 | 0.03 |
| Stochastic Oscillator | 53.77 | 58.75 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.